BRPI0520821A2 - fenofibrate pharmaceutical formulations with improved bioavailability - Google Patents

fenofibrate pharmaceutical formulations with improved bioavailability

Info

Publication number
BRPI0520821A2
BRPI0520821A2 BRPI0520821-1A BRPI0520821A BRPI0520821A2 BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2 BR PI0520821 A BRPI0520821 A BR PI0520821A BR PI0520821 A2 BRPI0520821 A2 BR PI0520821A2
Authority
BR
Brazil
Prior art keywords
fenofibrate
pharmaceutical formulations
improved bioavailability
polyethylene
fenofibrate pharmaceutical
Prior art date
Application number
BRPI0520821-1A
Other languages
Portuguese (pt)
Inventor
E Itzhak Lerner
Vered Rosenberger
Moshe Flashner-Barak
Anna Drabkin
Naomi Moldavski
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0520821A2 publication Critical patent/BRPI0520821A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

FORMULAçõES FARMACêUTICAS DE FENOFIBRATO COM BIODISPONIBILIDADE MELHORADA. São fornecidas composições farmacêuticas de fenofibrato, e formas de dosagem que as contém, que incluem fenofibrato, um polietileno glicol e um polietileno-propileno glicol; em que as composições são constituídas por sublimação de um portador sublimável com base em uma combinação de fenofibrato, o polietileno glicol e o polietileno-propíleno glicol com o portador sublimável, por exemplo, mentol.PHARMACEUTICAL FORMULATIONS OF PHENOPHYRATE WITH IMPROVED BIODAVAILABILITY. Fenofibrate pharmaceutical compositions and dosage forms containing them are provided, including fenofibrate, a polyethylene glycol and a polyethylene propylene glycol; wherein the compositions are sublimation of a sublimable carrier based on a combination of fenofibrate, polyethylene glycol and polyethylene propylene glycol with the sublimable carrier, e.g. menthol.

BRPI0520821-1A 2005-12-28 2005-12-28 fenofibrate pharmaceutical formulations with improved bioavailability BRPI0520821A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/047346 WO2007075171A1 (en) 2005-12-28 2005-12-28 Pharmaceutical formulations of fenofibrate having improved bioavailability

Publications (1)

Publication Number Publication Date
BRPI0520821A2 true BRPI0520821A2 (en) 2009-06-30

Family

ID=36499668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520821-1A BRPI0520821A2 (en) 2005-12-28 2005-12-28 fenofibrate pharmaceutical formulations with improved bioavailability

Country Status (7)

Country Link
JP (1) JP2009522258A (en)
CN (1) CN101351191A (en)
BR (1) BRPI0520821A2 (en)
CA (1) CA2634094A1 (en)
IL (1) IL192230A0 (en)
MX (1) MX2008008589A (en)
WO (1) WO2007075171A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773588A1 (en) * 2009-09-09 2011-03-17 Bernard Charles Sherman Choline fenofibrate delayed release compositions
DK2968529T3 (en) * 2013-03-14 2020-10-12 Aimmune Therapeutics Inc PREPARATION OF PEANUTY FORMULATIONS FOR ORAL DESENSIBILIZATION
KR101850119B1 (en) 2015-11-11 2018-04-20 제이투에이치바이오텍 (주) Novel Fenofibric Acid Prodrugs with Improved Bioavailability
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN112618511A (en) * 2020-12-31 2021-04-09 辰欣药业股份有限公司 Prescription composition of fenofibrate capsule and preparation process thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
CA2423335C (en) * 2000-09-20 2011-03-01 Rtp Pharma Inc. Spray drying process and compositions of fenofibrate
MXPA04009385A (en) * 2002-03-26 2005-01-25 Teva Pharma Drug microparticles.
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
JP2007508249A (en) * 2003-10-10 2007-04-05 ライフサイクル ファーマ アクティーゼルスカブ Solid dosage form containing fibrates and statins

Also Published As

Publication number Publication date
IL192230A0 (en) 2008-12-29
WO2007075171A1 (en) 2007-07-05
MX2008008589A (en) 2009-02-25
CA2634094A1 (en) 2007-07-05
JP2009522258A (en) 2009-06-11
CN101351191A (en) 2009-01-21

Similar Documents

Publication Publication Date Title
ES2525410T3 (en) Compositions and methods for the treatment of dermal hyperproliferative diseases
CL2007003244A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
GT199900203A (en) CELECOXIB COMPOSITIONS.
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
RS50660B (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
UY30759A1 (en) CHEMICAL COMPOUNDS
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2004000930A1 (en) COMPOUND DERIVED FROM DEFINED FORMULA DIHYDROQUINAZOLINE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF VIRAL INFECTIONS; PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND USE OF THE COMPOUND IN THE PREPARATION OF MEDICINES.
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
BRPI0620229A8 (en) formulation
BRPI0922364A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
CO6362017A2 (en) THERAPEUTIC ANTIVIRAL PEPTIDES
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
CL2008003511A1 (en) Nucleotide derived compounds, hepatitis c virus ns5b polymerase inhibitors; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
BRPI0510422A (en) transparent microemulsion-based cosmetic formulation containing an alpha-hydroxycarboxylic acid
CL2008001024A1 (en) Phthalazinone derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of cardiovascular diseases, parkinson's, inflammatory diseases, multiple sclerosis, cancer, among others
CL2007003540A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE SERINE PROTEASE OF HEPATITIS C; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
GT200800107A (en) ORAL FORMULATIONS THAT INCLUDE TIGECICLINE
CL2007001752A1 (en) Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.
CL2009000281A1 (en) Compounds derived from 5,6-dihydro-pyrrolo- [2,1-a] -isoquinolines and pyrrolo- [2,1-a] -isoquinolines; pharmaceutical composition comprising said compounds; and use for the treatment of fertility disorders.
BRPI0520821A2 (en) fenofibrate pharmaceutical formulations with improved bioavailability
DK1729732T3 (en) Anionic hydrogel matrices with pH-dependent release as drug carriers

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.